- Home
- XOMAO vs ELAN Comparison
XOMAO vs ELAN Comparison
Compare XOMAO & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAO
- ELAN
- Stock Information
- Founded
- XOMAO N/A
- ELAN 1954
- Country
- XOMAO United States
- ELAN United States
- Employees
- XOMAO 13
- ELAN N/A
- Industry
- XOMAO Biotechnology: Pharmaceutical Preparations
- ELAN Biotechnology: Pharmaceutical Preparations
- Sector
- XOMAO Health Care
- ELAN Health Care
- Exchange
- XOMAO Nasdaq
- ELAN Nasdaq
- Market Cap
- XOMAO N/A
- ELAN 6.0B
- IPO Year
- XOMAO N/A
- ELAN 2018
- Fundamental
- Price
- XOMAO $25.25
- ELAN $13.45
- Analyst Decision
- XOMAO
- ELAN Buy
- Analyst Count
- XOMAO 0
- ELAN 6
- Target Price
- XOMAO N/A
- ELAN $15.17
- AVG Volume (30 Days)
- XOMAO N/A
- ELAN 7.4M
- Earning Date
- XOMAO N/A
- ELAN 05-07-2025
- Dividend Yield
- XOMAO N/A
- ELAN N/A
- EPS Growth
- XOMAO N/A
- ELAN N/A
- EPS
- XOMAO N/A
- ELAN 0.75
- Revenue
- XOMAO N/A
- ELAN $4,427,000,000.00
- Revenue This Year
- XOMAO N/A
- ELAN $3.85
- Revenue Next Year
- XOMAO N/A
- ELAN $4.88
- P/E Ratio
- XOMAO N/A
- ELAN $17.93
- Revenue Growth
- XOMAO N/A
- ELAN 1.42
- 52 Week Low
- XOMAO N/A
- ELAN $8.02
- 52 Week High
- XOMAO N/A
- ELAN $18.80
- Technical
- Relative Strength Index (RSI)
- XOMAO 52.57
- ELAN 70.69
- Support Level
- XOMAO $25.10
- ELAN $12.40
- Resistance Level
- XOMAO $25.30
- ELAN $14.20
- Average True Range (ATR)
- XOMAO 0.11
- ELAN 0.46
- MACD
- XOMAO 0.03
- ELAN 0.02
- Stochastic Oscillator
- XOMAO 71.45
- ELAN 60.53
About XOMAO AGNC Investment Corp.
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
About ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.